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ARTICLE
Functional Variants in the Promoter Region of Chitinase 3–Like 1
(CHI3L1) and Susceptibility to Schizophrenia
Xinzhi Zhao,* Ruqi Tang,* Bo Gao, Yongyong Shi, Jian Zhou, Shengzhen Guo, Jing Zhang,
Yabing Wang, Wei Tang, Junwei Meng, Sheng Li, Hongsheng Wang, Gang Ma, Chuwen Lin,
Yue Xiao, Guoyin Feng, Zhiguang Lin, Shaomin Zhu, Yangling Xing, Hong Sang,
David St. Clair, and Lin He
The chitinase 3–like 1 gene (CHI3L1) is abnormally expressed in the hippocampus of subjects with schizophrenia and
may be involved in the cellular response to various environmental events that are reported to increase the risk of
schizophrenia. Here, we provide evidence that the functional variants at the CHI3L1 locus influence the genetic risk of
schizophrenia. First, using case-control and transmission/disequilibrium–test (TDT) methodologies, we detected a sig-
nificant association between schizophrenia and haplotypes within the promoter region of CHI3L1 in two independent
cohorts of Chinese individuals. Second, the at-risk CCC haplotype ( and .0018 in case-control and TDT studies,Pp .00058
respectively) revealed lower transcriptional activity ( ) and was associated with lower expression (57Pp 2.2# 10 Pp
) compared with neutral and protective haplotypes. Third, we found that an allele of SNP4 (rs4950928), the553.1# 10
tagging SNP of CCC, impaired the MYC/MAX–regulated transcriptional activation of CHI3L1 by altering the transcrip-
tional-factor consensus sequences, and this may be responsible for the decreased expression of the CCC haplotype. In
contrast, the protective TTG haplotype was associated with a high level of CHI3L1 expression. Our findings identify
CHI3L1 as a potential schizophrenia-susceptibility gene and suggest that the genes involved in the biological response
to adverse environmental conditions are likely to play roles in the predisposition to schizophrenia.
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Schizophrenia (MIM 181500) is a common, complex ma-
jor mental disorder affecting ∼1% of the population world-
wide.1 Clinical and epidemiological investigations indi-
cate that schizophrenia is a multifactorial disorder with
genetic and environmental elements contributing to over-
all risk.2 A number of environmental factors, including
obstetric complications, prenatal exposure to infection or
famine, and psychosocial stressors, have been reported as
risk factors of schizophrenia.2–5 An adverse environment
can produce physiological and/or psychological stress,
which, in turn, may result in brain dysfunctions. A key
period of vulnerability to environmental stress may be
during brain development. This is consistent with current
concepts that view schizophrenia as primarily a disorder
of neurodevelopment.6 However, sensitivity to environ-
mental stressors shows substantial interindividual varia-
tion, and at least part of this variation may be genetic in
origin and/or involve gene-environment interactions.
The chitinase 3–like 1 gene (CHI3L1 [MIM 601525]), lo-
cated on chromosome 1q32.1, a region that shows weak
linkage to schizophrenia,7 has been reported to display
disease-specific alteration in gene expression in the hip-
pocampus of patients with schizophrenia.8 One function
of CHI3L1 is to act as a cellular survival factor in response
to an adverse environment: various types of physiological
stress, such as inflammation, hypoxia, and nutrient dep-
rivation, may induce high expression of CHI3L1.9,10 The
presence of CHI3L1 protein inhibits the activity of ASK1,11
which is pivotal for the transmission of stress-induced cel-
lular responses, and protects the cells from undergoing
apoptosis.
Here, we present evidence that CHI3L1 contributes to
the genetic risk factors of schizophrenia. We have ob-
served significant association between schizophrenia and
genetic variations in the CHI3L1 locus in both family-
based and population-based investigations. Moreover, the
CHI3L1 haplotypes implicated in schizophrenia suscep-
tibility were associated with the altered expression level
of the gene. Cis-acting effects of the functional variants
in CHI3L1 may be responsible for the association.
Material and Methods
Subjects
For the case-control investigation, 412 unrelated patients with
schizophrenia and 464 control individuals were recruited in this
study. The patient group consisted of 200 men and 212 women
with a mean  SD age of 41.13 12.97 years. The control group
consisted of 200 men and 264 women with a mean age of 34.88
www.ajhg.org The American Journal of Human Genetics Volume 80 January 2007 13
Figure 1. Genomic structure of CHI3L1 and the location of SNPs
included in the present study.
 10.37 years. A subgroup of samples including 29 patients (15
men and 14 women with a mean age of 39.68  12.66 years)
and 54 controls (27 men and 27 women with a mean age of 39.66
 11.99 years) was used to investigate gene expression. All the
population-based samples were from Shanghai, East China. For
the transmission/disequilibrium–test (TDT) study, 308 unrelated
probands with schizophrenia and their biological parents were
recruited. The probands consisted of 163 males and 145 females
with a mean age of 24.0  6.6 years, of whom 128 were from
Shanghai, 65 from Xi’an, 35 from Changchun, and 80 from Jilin.
Subjects with schizophrenia were given strict diagnoses according
to the criteria of the DSM-IV, with the use of a combination of
examination of psychiatric case records and clinical interviews,
which used the Chinese version of the Schedule for Affective
Disorders and Schizophrenia–Lifetime (SADS-L). The diagnoses
were checked and verified by another independent senior psy-
chiatrist who reviewed the psychiatric case records. A total of
1,800 subjects, including 720 patients with schizophrenia, were
recruited in this study. All subjects were Han Chinese in origin.
Participants gave a standard informed consent in the protocol,
which was reviewed and approved by the Shanghai Ethical Com-
mittee of Human Genetic Resources, after the nature of the study
had been fully explained.
Genotyping
All five SNPs were selected from dbSNP. SNP1, SNP2, and SNP5
were scored using a single-nucleotide primer extension (SNuPe)
method with MegaBACE SNuPe genotyping kit (Amersham Bio-
sciences) and the primers that anneal 1 b upstream of the target
SNPs. A complementary-labeled dideoxynucleotide triphosphate
was added at the SNP site in the reaction. The SNuPe products
were then cleaned and were electrophoresed on MegaBACE 1000
instruments (Amersham Biosciences). SNP3 and SNP4 were ge-
notyped using direct sequencing on ABI 3100 instruments (Ap-
plied Biosystems).
Cell Culture, Transfection, and MYC-Inhibitor Trial
U251 cells were cultured in Dulbecco’s modified Eagle medium
(Gibco-BRL) with 10% fetal bovine serum (FBS) and penicillin-
streptomycin at 37C and 5% CO2. Transient transfection for the
luciferase reporter assay was performed in a 48-well plate with
use of LipofectAmine 2000 regent (Invitrogen), and pCBR control
vector (Promega) was used to correct for transfection efficiency.
For each well, 0.2 mg pCBG99 plasmid (Promega) containing a
1.3-kb CHI3L1 promoter fragment and 0.2 mg pCBR control plas-
mid were added. The Chroma-Glo luciferase assay system (Pro-
mega) was used to measure the relative transcriptional activities
of the CHI3L1 haplotypes after they were cultured for 36 h. THP-
1 cells were maintained in RPMI 1640 medium (Gibco-BRL) sup-
plemented with 10% FBS and penicillin-streptomycin. To selec-
tively block the MYC signaling pathway in U251 and THP-1, cells
were cultured for 72 h in the corresponding mediums containing
64 mM MYC inhibitor and 2.5% FBS.
Nuclear-Extraction Preparation and Electrophoretic Mobility
Shift Assay
Nuclear proteins were extracted using NE-PER Reagents (Pierce).
Electrophoretic mobility shift assays (EMSAs) were performed us-
ing gel shift assay systems (Promega) under the guidelines pro-
vided. Oligonucleotides were end-labeled with [g-32P] ATP with
use of T4 polynucleotide kinase. The binding reaction contained
8 mg of nuclear-extract proteins, 1# binding buffer, and, if
needed, unlabeled competitors; labeled probes were added after
10 min, and samples were incubated at room temperature for a
total of 30 min. For the supershift assay, nuclear-extract proteins,
labeled probes, and antisera were incubated for 16 h at 4C. Sam-
ples were analyzed by electrophoresis on 4% (w/v) native poly-
acrylamide gels. The gels were dried and were autoradiographed
for 3 h or overnight.
RNA Extraction and cDNA Synthesis
Total RNA was extracted using Trizol reagent. RNA integrity was
confirmed by direct visualization of 18S and 28S rRNA bands after
agarose-gel electrophoresis. RNA samples were incubated using
10 units of DNase I (Novagen) at 37C for 20 min to remove
residual DNA, followed by inactivation at 65C for 10 min. RNA
samples were further purified using a HiBind spin column
(Omega) in accordance with the manufacturer’s instructions. The
purified RNA samples (0.5 mg) were then reverse transcribed using
the SuperScript first-strand synthesis system (Invitrogen) and ran-
dom hexamers.
Real-Time Quantitative PCR and Allele-Specific Expression
Assay
Real-time PCR was performed using the ABI7900 system (Applied
Biosystems). Reactions were performed in a 10-ml volume includ-
ing diluted cDNA samples, primers, and SYBR Green I Mastermix
(Applied Biosystems). Diluted cDNA samples produced from 10
ng total RNA were added to each well. Real-time PCR data were
collected using SDS software (version 2.1 [Applied Biosystems]).
Expression of CHI3L1 was normalized in relation to GAPDH levels
(denoted as DCt). Both GAPDH and CHI3L1 were tested four times
for each sample. SNP5 within exon 5 was used as a marker for
the allele-specific expression assay. The SNuPe method was used
to compare relative allelic expression in individual subjects who
were heterozygous for the marker polymorphisms. To normalize
the signal from different fluorescent dyes, genomic DNA with a
perfect 1:1 ratio of the two alleles was used to correct allelic ratios
obtained from each cDNA analysis. The SnuPe products of DNA
and cDNA templates from the same samples were electrophoresed
in the same capillaries in one run, by multiple injections.
Risperidone Trial
Risperidone (Xian Janssen-Cliag) was dissolved in saline and was
administered to C57Bl/6 mice (1 mg/kg) daily. Control mice re-
ceived the vehicle alone. All the mice were housed, five per cage,
at room temperature with a 12-h light/dark cycle. For each group,
5 male and 5 female mice were included. Mice received risperi-
done or the vehicle for 3 wk and were killed 2 h after the final
trial.
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Table 1. Genetic Association Analyses of the CHI3L1 Gene with Schizophrenia
Allele/
Haplotype
Marker and
Alleles or
Haplotype
dbSNP
Identification
Case-Control Study No.
and Allelic Frequency
(%)
Odds
Ratio
TDT Study
Patients Controls Pa T/NTb Pc
C SNP1 (C/T) rs2364574 224 (28.4) 237 (25.8) 1.14 .24 … …
T SNP2 (C/T) rs6691378 234 (29.4) 316 (34.3) .80 .028 178/208 (.86) .07
T SNP3 (C/T) rs10399805 227 (28.7) 313 (34.1) .78 .016 161/198 (.81) .019
C SNP4 (G/C) rs4950928 137 (17.4) 114 (12.4) 1.49 .0039 88/56 (1.57) .0042
G SNP5 (G/A) rs880633 303 (37.2) 340 (36.9) 1.01 .88 … …
CCG SNP2 haplotype … 398 (50.7) 475 (51.8) .97 .67 315/310 (1.01) .77
TTG SNP3 haplotype … 204 (26.1) 289 (31.5) .77 .013 153/187 (.82) .032
CCC SNP4 haplotype … 135 (17.2) 104 (11.3) 1.62 .00058 93/57 (1.63) .0018
Global … … … … … .0018 … .024
a P values, not corrected for multiple tests, in population-based samples.
b Number of transmitted (T) and untransmitted (NT) alleles or haplotypes. T/NT ratios are shown in parentheses.
c P values, not corrected for multiple tests, in family-based samples.
Table 2. Estimates of LD Statistics between
All Pairs of Markers
Marker
LD Statisticsa
SNP1 SNP2 SNP3 SNP4 SNP5
SNP1 .89 .81 .29 .61
SNP2 .14 .88/.96 .86/.91 .40
SNP3 .11 .75/.79 .95/.94 .36
SNP4 .04 .06/.07 .07/.07 .98
SNP5 .08 .05 .04 .10
a D′ values are shown above the diagonal; r2 values are
shown below the diagonal. LD values in family trios are
shown after the slash.
Figure 2. Luciferase reporter assay of SNP2, SNP3, and SNP4
common haplotypes in U251 cells. The transcriptional activity of
the pCBG99 control was set at 100%. Each CHI3L1 haplotype was
tested eight times. Among the haplotypes, the risk haplotype (CCC)
revealed the lowest activity, whereas the protective haplotype
(TTG) showed the highest activity ( , by one-way7Pp 2.2# 10
ANOVA).
Statistical Analysis
A SHEsis12 software platform was used to analyze deviation from
Hardy-Weinberg equilibrium, pairwise linkage disequilibrium
(LD), and genetic association of the polymorphisms in the case-
control study. For TDT analysis, the TDTPHASE13 program of the
UNPHASED set was used for single and multiple marker-haplo-
type transmission analyses and for estimating the LD between
the adjacent markers. Group comparisons for the dual luciferase–
reporter genes assay, expression analyses, and comparative allele
representation were analyzed using an unpaired two-tailed t test
or a Mann-Whitney U test or, if there were more than two groups,
a one-way ANOVA or Kruskal-Wallis H test.
Results
The CHI3L1 gene spans 8 kb in the human genome. We
selected markers from the dbSNP database and used se-
quencing to screen new polymorphisms in 16 individuals.
We typed five SNPs at the CHI3L1 locus (fig. 1) in 412
patients with schizophrenia and 464 unaffected controls.
The genotypic distributions of all the markers were in ac-
cordance with Hardy-Weinberg equilibrium ( ) inP 1 .05
each set of samples. SNP5 was the only common variant
present in the coding sequences, but there was no differ-
ence in the allelic frequency between patients and con-
trols. However, three SNPs (i.e., SNP2, SNP3, and SNP4)
in the promoter region of the gene revealed allelic asso-
ciation with schizophrenia (table 1). To attempt to confirm
these findings, we performed the TDT in a fully indepen-
dent cohort of 311 proband-parent triads. We found sig-
nificant transmission distortions of SNP3 and SNP4 but
failed to replicate the association of SNP2. LD estimates
of pairwise markers, expressed in D′ and r2, are presented
in table 2. With consideration of the tight LD between
SNP2 and SNP3 ( and 0.79 in population- and2r p 0.75
family-based samples, respectively), the positive result of
SNP2 in the case-control study could be explained as LD
with SNP3. However, the association results of SNP3 and
SNP4 appear to be independent of each other ( ).2r ! 0.1
In haplotypic analysis, three common haplotypes (with
probability 13%) constructed from SNP2, SNP3, and SNP4
were observed (table 1). The CCC haplotype was associ-
ated with higher risk of schizophrenia ( andPp .00058
.0018 in population- and family-based samples, respec-
tively). The association remained significant in both case-
control and TDT studies, even after a stringent Bonferroni
correction ( , corrected for 16 tests) was applied. An-P ! .03
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Figure 3. In vitro binding of U251 nuclear proteins to CHI3L1
promoter sequences containing SNP3 and SNP4. In lanes 1–4 and
9–10, probes of major alleles for each SNP were loaded. In lanes
5–8, probes of minor alleles for each SNP were loaded. Competitors
are the unlabeled oligonucleotides with same allele as probes, and
cross-competitors are the oligonucleotides with the other allele
of probes. a, No obvious difference shown between the two alleles
of SNP3. b, G-allele probes of SNP4 generating two binding com-
plexes (lane 2), whereas C-allele probes generated one (lane 6).
Loading 100# cross-competitors (C allele) does not eliminate the
G-allele–specific band (lane 4). c, Supershift assay for the G-allele
probes of SNP4 with use of antibodies of AP-2 and MYC. The pres-
ence of either of the antibodies resulted in a visible supershift
band.
Figure 4. Effect of inhibition of the MYC/MAX signaling path-
ways on CHI3L1 expression. In both cell lines, MYC-inhibitor trial
severely reduces expression level of CHI3L1 (76% decreased in
U251 and 82% decreased in THP-1). Double asterisk (**) indicates
.P ! .01
other TTG haplotype was associated with lower risk of
schizophrenia ( and .032 in population- and fam-Pp .013
ily-based samples, respectively). We also determined that
SNP3 was the tagging SNP (tSNP) of TTG, whereas SNP4
was the tSNP of CCC.
Genetic variations in the promoter region can influence
gene expression by changing the rate of transcription. We
cloned DNA fragments that contain the three common
haplotypes constructed from SNP2, SNP3, and SNP4 into
luciferase reporter vectors and compared their relative
transcription activities in a human glioblastoma cell line
(U251). The haplotypes implicated in schizophrenia sus-
ceptibility were associated with significant reporter-activ-
ity difference ( ) (see fig. 2). The risk hap-7Pp 2.2# 10
lotype CCC showed lower activity (28% lower) than the
neutral haplotype CCG. By contrast, the protective hap-
lotype TTG represented higher activity (47% higher) than
CCG.
SNP3 and SNP4 are located in the core promoter region
of CHI3L1. We used EMSAs to determine whether the ge-
netic variants would alter DNA-protein interaction. The
probes of both alleles of SNP3 produced one binding com-
plex with U251 nuclear-extract proteins, but there was no
difference between the two alleles (fig. 3a). As for SNP4,
the C-allele probe generated one clear binding complex
with nuclear extract, but the G-allele probe generated two.
The additional complex with lower mobility can still re-
main visible after the 100# C-allele cross-competitor is
loaded (fig. 3b).
The SNP4 GrC transversion appeared to alter the con-
sensus sequences of several transcription factors, on the
basis of analyses with Genomatix software.14 We predicted
that MYC/MAX and AP-2 would be promising candidates
and performed supershift analysis with use of the mono-
clonal antibodies to MYC and AP-2. The addition of either
of these antibodies resulted in weakness of the G-allele–
specific band; however, the intensity of the supershifted
bands was too low for reliable visualization. Lengthening
of the exposure time (overnight) enabled good observa-
tion of the supershift bands (fig. 2c). AP-2 is a negative
regulator to MYC-mediated transcriptional activation
when their binding sites are adjacent.15 Hence, our further
investigation was focused on the role of MYC/MAX in
CHI3L1 transcription. We treated U251 and THP-1 (hu-
man monocytic cell line) cells with MYC inhibitor, which
interfered with the interaction between MYC and MAX.16
We detected a severely decreased CHI3L1 expression in
both cell lines (fig. 4), which pointed to an active MYC/
MAX binding site in the promoter region of CHI3L1 being
involved in controlling the expression of this gene. The
SNP4 GrC polymorphism may, therefore, influence gene
expression by impairing the MYC/MAX–regulated tran-
scriptional activity. Meanwhile, similar results in the glial-
derived and lymphoid-derived cells indicated that the ef-
fect of SNP4 may be common in the blood and in the
brain.
We used real-time PCR to quantify the gene expression
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Figure 5. Expression analyses of CHI3L1 in vivo. a, Expression level of CHI3L1 in the PBC from patients with schizophrenia and
unaffected controls. The average level of CHI3L1 in unaffected controls was defined as 100. No significant difference in expression level
between the two groups was detected (t test ). b and c, Expression of CHI3L1 was associated with the genotype of bothPp .081
SNP4 (b) and SNP3 (c) in PBC (Kruskal-Wallis H test ). d, Haplotypes in the promoter region of CHI3L1 associated with expressionP ! .01
level of the gene in PBC. e, Relative allele-specific expression of the SNP5 data expressed as allele ratios of A/G. Patients who were
heterozygotes for SNP4 revealed highly significant allele differences (t test , corrected for 5 tests) f, Risperidone-treated6Pp 9.1# 10
mice did not change the mRNA level of CHI3L1 in blood and brain (t test ). The expression level of CHI3L1 in untreated miceP 1 .05
was defined as 100.
in the peripheral blood cells (PBC) isolated from 82 in-
dividuals. The expression of CHI3L1 was decreased by 19%
in 29 patients compared with its expression in 53 controls,
but there was no statistically significant difference be-
tween the two groups ( ) (fig. 3a). The samplesPp .081
were then grouped together for analysis. The CHI3L1 ex-
pression level was obviously correlated with genotypes of
SNP4 ( , corrected for 5 tests) (fig. 5b), as well5Pp 4.2# 10
as with genotypes of SNP3 ( , corrected for4Pp 7.6# 10
5 tests) (fig. 5c). We determined the precise haplotypic
structures of the 82 samples by cloning and sequencing
the DNA fragments containing SNP2, SNP3, and SNP4.
There was a significant association between gene expres-
sion and common haplotypes ( , corrected5Pp 3.1# 10
for 5 tests) (fig. 5d).
To minimize the trans-acting influences, we performed
an allele-specific expression assay,17 using SNP5 as a mar-
ker for mRNA transcribed from each chromosomal allele.
The objective of the assay was to determine the allele-
specific expression pattern of SNP4: the C alleles of SNP4
were almost always in linkage with the A alleles of SNP5
( ), and, therefore, the comparative expression ra-′D p 0.98
tio of A/G in SNP5 represented that of C/G in SNP4 for
the samples that were heterozygous in both loci. In total,
33 samples that were heterozygous in SNP5 were used in
the current assay. When the data from all the samples were
combined, the comparative allelic ratios of A/G were wide-
spread. However, in the six samples that were also het-
erozygous in SNP4, the expression of the A allele was sig-
nificantly reduced by ∼80% compared with the G allele
( , corrected for 5 tests) (fig. 5e). This result6Pp 9.1# 10
further indicated that the C allele of SNP4 was responsible
for the reduced CHI3L1 expression. The data from the
quantitative PCR and allele-specific expression assay sup-
ported the cis-acting role of SNP4 in gene expression in
vivo.
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Figure 6. Hypothetical scenario for CHI3L1 in the pathophysi-
ology of schizophrenia. Impairment of AKT signaling and over-
activation of immune responses were observed in the subjects with
schizophrenia and were considered to contribute to the risk of
schizophrenia. The CHI3L1 gene may partly compensate the al-
teration of the processes and, therefore, may play a role in pre-
venting the progression of psychosis.
In view of the possible effects on gene expression data
from antipsychotic medication in the probands with
schizophrenia, we examined the CHI3L1 expression level
after risperidone treatment, since most patients recruited
for the expression studies were receiving this treatment.
Our results indicated that risperidone treatment does not
change the CHI3L1 mRNA level in vivo (fig. 5f).
Discussion
In this study, we observed positive association between
schizophrenia and genetic variations in the promoter re-
gion of the CHI3L1 gene in two independent cohorts of
Chinese patients with schizophrenia. The association re-
mained significant in both population-based and family-
based investigations after correction for multiple tests. Our
combined findings made it unlikely that they are the result
of a type I error and ruled out the possibility that strati-
fication could explain the results. However, we cannot
formally exclude the possibility that the observed asso-
ciation signal originates from genes in the vicinity of the
CHI3L1 locus and not from the CHI3L1 locus itself. Further
detailed LD-mapping studies performed in different pop-
ulations are essential. Nevertheless, CHI3L1 is a promising
candidate gene for schizophrenia, and the parallel func-
tional evidence reinforces our positive association find-
ings. We have demonstrated that the individuals carrying
risk alleles/haplotypes have lower expression levels of
CHI3L1 than do those carrying protective alleles/haplo-
types. The effect is also greater in individuals carrying two
copies of the risk alleles/haploypes. Our results strongly
indicate that susceptibility variants in the CHI3L1 locus
are likely to exert their effect mainly by changing the
abundance of gene production. Furthermore, SNP4, which
gives the strongest association with schizophrenia, is a
good candidate for such a susceptibility variant, since the
GrC transversion impairs the MYC/MAX–regulated tran-
scriptional activity, which, in turn, can account for the
reduced expression of the risk haplotype.
The genetic variations that change the expression of
CHI3L1 may influence some key processes that are
CHI3L1-dosage dependent. One is activation of AKT-me-
diated signal pathways through phosphatidylinositol-3
kinase (PI-3K)–dependent phosphorylation.18 There is
strong convergent evidence indicating that the PI-3K/AKT
signal pathway is implicated in schizophrenia; AKT1-
GSK3b, a component of AKT-mediated signals pathway, is
impaired in patients with schizophrenia, and antipsy-
chotic medication may induce AKT activation, to com-
pensate for the impairment.19 An additional possibility is
that CHI3L1 participates in the pathophysiology of schizo-
phrenia through its function on the immune response.
Activation of the inflammatory response system has been
observed in schizophrenia and affective disorders.20,21
High levels of inflammatory cytokines, the immune me-
diators, have an effect on neuronal survival22 and result
in neurobehavioral deficits in animal models.23 CHI3L1
may have an inhibitory effect on these inflammatory re-
sponses24 and provides a negative-feedback control for the
action of inflammatory cytokines.10 These functional ob-
servations suggest a role of the CHI3L1 gene in preventing
the progression of psychosis (fig. 6), whereas the func-
tional variations that reduce expression levels may in-
crease the genetic risk of developing schizophrenia.
AKT and cytokines, as well as CHI3L1, play a role in cell
response to an adverse environment; it has long been
known that the production of inflammatory cytokines is
stimulated by the stress coupled with adverse environ-
mental events.21 The AKT pathway has been strongly as-
sociated with cell survival25,26 and regulates the cytokine-
induced cellular responses.27 Certain genes involved in
PI-3K/AKT and cytokine signaling have been reported to
be associated with schizophrenia.19,28–30 It will be of inter-
est to investigate the interaction between these genes and
CHI3L1 under adverse environmental circumstances and
the possible effects of epistasis between the genes on the
genetic susceptibility to schizophrenia.
In conclusion, our findings identify CHI3L1 as a poten-
tial schizophrenia-susceptibility gene. Data from genetic
and molecular analyses provide clear and consistent evi-
dence for the functional SNP4 to be a strong candidate
for a risk factor of schizophrenia. Moreover, our results,
together with the previously published observations, sup-
port the proposal that genes involved in biological re-
sponse to adverse environmental conditions play roles in
the predisposition to schizophrenia.
18 The American Journal of Human Genetics Volume 80 January 2007 www.ajhg.org
Acknowledgments
This work was supported by grants from the Key Grant Project
of the Chinese Ministry of Education (grant 10414), People’s Re-
public of China, and the 973 projects (2001CB510304).
Web Resources
The URLs for data presented herein are as follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (for SNP1–SNP5)
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for schizophrenia and CHI3L1)
References
1. Lewis DA, Lieberman JA (2000) Catching up on schizophre-
nia: natural history and neurobiology. Neuron 28:325–334
2. Tsuang M (2000) Schizophrenia: genes and environment. Biol
Psychiatry 47:210–220
3. Cannon M, Jones PB, Murray RM (2002) Obstetric compli-
cations and schizophrenia: historical and meta-analytic re-
view. Am J Psychiatry 159:1080–1092
4. St Clair D, Xu M, Wang P, Yu Y, Fang Y, Zhang F, Zheng X,
Gu N, Feng G, Sham P, et al (2005) Rates of adult schizo-
phrenia following prenatal exposure to the Chinese famine
of 1959–1961. JAMA 294:557–562
5. Jones P, Cannon M (1998) The new epidemiology of schizo-
phrenia. Psychiatr Clin North Am 21:1–25
6. Rapoport JL, Addington AM, Frangou S, Psych MR (2005) The
neurodevelopmental model of schizophrenia: update 2005.
Mol Psychiatry 10:434–449
7. Shaw SH, Kelly M, Smith AB, Shields G, Hopkins PJ, Loftus
J, Laval SH, Vita A, De Hert M, Cardon LR, et al (1998) A
genome-wide search for schizophrenia susceptibility genes.
Am J Med Genet 81:364–376
8. Chung C, Tallerico T, Seeman P (2003) Schizophrenia hip-
pocampus has elevated expression of chondrex glycoprotein
gene. Synapse 50:29–34
9. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE
(2005) Regulation of YKL-40 expression during genotoxic or
microenvironmental stress in human glioblastoma cells. Can-
cer Sci 96:183–190
10. Recklies AD, Ling H, White C, Bernier SM (2005) Inflam-
matory cytokines induce production of CHI3L1 by articular
chondrocytes. J Biol Chem 280:41213–41221
11. Ling H, Recklies AD (2004) The chitinase 3-like protein hu-
man cartilage glycoprotein 39 inhibits cellular responses to
the inflammatory cytokines interleukin-1 and tumour necro-
sis factor-alpha. Biochem J 380:651–659
12. Shi YY, He L (2005) SHEsis, a powerful software platform for
analyses of linkage disequilibrium, haplotype construction,
and genetic association at polymorphism loci. Cell Res 15:
97–98
13. Dudbridge F (2003) Pedigree disequilibrium tests for multi-
locus haplotypes. Genet Epidemiol 25:115–121
14. Werner T (2000) Computer-assisted analysis of transcription
control regions: Matinspector and other programs. Methods
Mol Biol 132:337–349
15. Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner
R, Eilers M (1995) Transcriptional activation by Myc is under
negative control by the transcription factor AP-2. EMBO J 14:
1508–1519
16. Yin X, Giap C, Lazo JS, Prochownik EV (2003) Low molecular
weight inhibitors of Myc-Max interaction and function. On-
cogene 22:6151–6159
17. Knight JC (2004) Allele-specific gene expression uncovered.
Trends Genet 20:113–116
18. Recklies AD, White C, Ling H (2002) The chitinase 3-like
protein human cartilage glycoprotein 39 (HC-gp39) stimu-
lates proliferation of human connective-tissue cells and ac-
tivates both extracellular signal-regulated kinase- and protein
kinase B-mediated signalling pathways. Biochem J 365:119–
126
19. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos
JA (2004) Convergent evidence for impaired AKT1-GSK3beta
signaling in schizophrenia. Nat Genet 36:131–137
20. Prolo P, Licinio J (1999) Cytokines in affective disorders and
schizophrenia: new clinical and genetic findings. Mol Psy-
chiatry 4:109–111
21. Kronfol Z, Remick DG (2000) Cytokines and the brain: im-
plications for clinical psychiatry. Am J Psychiatry 157:683–
694
22. Marx CE, Jarskog LF, Lauder JM, Lieberman JA, Gilmore JH
(2001) Cytokine effects on cortical neuron MAP-2 immu-
noreactivity: implications for schizophrenia. Biol Psychiatry
50:743–749
23. Tohmi M, Tsuda N, Watanabe Y, Kakita A, Nawa H (2004)
Perinatal inflammatory cytokine challenge results in distinct
neurobehavioral alterations in rats: implication in psychiatric
disorders of developmental origin. Neurosci Res 50:67–75
24. van Bilsen JH, van Dongen H, Lard LR, van der Voort EI,
Elferink DG, Bakker AM, Miltenburg AM, Huizinga TW, de
Vries RR, Toes RE (2004) Functional regulatory immune re-
sponses against human cartilage glycoprotein-39 in health
vs. proinflammatory responses in rheumatoid arthritis. Proc
Natl Acad Sci USA 101:17180–17185
25. Brazil DP, Hemmings BA (2001) Ten years of protein kinase
B signalling: a hard Akt to follow. Trends Biochem Sci 26:
657–664
26. Scheid MP, Woodgett JR (2001) PKB/AKT: functional insights
from genetic models. Nat Rev Mol Cell Biol 2:760–768
27. Kim AH, Khursigara G, Sun X, Franke TF, Chao MV (2001)
Akt phosphorylates and negatively regulates apoptosis signal-
regulating kinase 1. Mol Cell Biol 21:893–901
28. Stopkova P, Saito T, Papolos DF, Vevera J, Paclt I, Zukov I,
Bersson YB, Margolis BA, Strous RD, Lachman HM (2004)
Identification of PIK3C3 promoter variant associated with bi-
polar disorder and schizophrenia. Biol Psychiatry 55:981–988
29. Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli
M (2001) Association betweenG308A tumor necrosis factor
alpha gene polymorphism and schizophrenia. Mol Psychiatry
6:79–82
30. Chiavetto LB, Boin F, Zanardini R, Popoli M, Michelato A,
Bignotti S, Tura GB, Gennarelli M (2002) Association between
promoter polymorphic haplotypes of interleukin-10 gene
and schizophrenia. Biol Psychiatry 51:480–484
